Comparing Galena Biopharma (GALE) & Its Rivals
Galena Biopharma (NASDAQ: GALE) is one of 116 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Galena Biopharma to similar businesses based on the strength of its earnings, institutional ownership, analyst recommendations, risk, profitability, dividends and valuation.
Valuation & Earnings
This table compares Galena Biopharma and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Galena Biopharma||N/A||-$23.48 million||-0.22|
|Galena Biopharma Competitors||$8.20 billion||$2.68 billion||-1.31|
Galena Biopharma’s rivals have higher revenue and earnings than Galena Biopharma. Galena Biopharma is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This is a summary of recent ratings and target prices for Galena Biopharma and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Galena Biopharma Competitors||825||3701||6736||182||2.55|
Galena Biopharma currently has a consensus target price of $4.00, suggesting a potential upside of 937.34%. As a group, “Pharmaceuticals” companies have a potential upside of 23.34%. Given Galena Biopharma’s higher possible upside, equities research analysts clearly believe Galena Biopharma is more favorable than its rivals.
Institutional & Insider Ownership
20.5% of Galena Biopharma shares are held by institutional investors. Comparatively, 43.6% of shares of all “Pharmaceuticals” companies are held by institutional investors. 0.8% of Galena Biopharma shares are held by company insiders. Comparatively, 11.8% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This table compares Galena Biopharma and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Galena Biopharma Competitors||-2,845.52%||-66.83%||-8.68%|
Volatility and Risk
Galena Biopharma has a beta of 1.82, suggesting that its stock price is 82% more volatile than the S&P 500. Comparatively, Galena Biopharma’s rivals have a beta of 0.90, suggesting that their average stock price is 10% less volatile than the S&P 500.
Galena Biopharma rivals beat Galena Biopharma on 9 of the 12 factors compared.
Galena Biopharma Company Profile
Galena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company’s NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company’s therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient’s own immune system to seek out and attack any residual cancer cells.
Receive News & Ratings for Galena Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galena Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.